Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)

Top 10 Pipelines To Watch: 2019 Annual Report

Analysts, Ankylosing Spondylitis (AS), Annual Reports, Antiretroviral Drugs, Atopic Dermatitis (Eczema), Autoimmune Diseases, B Cells, BRCA Gene, BRCA mutation, Big Pharma, Biologics, Biopharma, Biotechnology, Blockbusters, Breakthrough Therapy Designation, Business, CAR-T Therapy, Cancer, Cells, Chemotherapy, Clinical Data, Clinical Trials, Collaborations, Crohn's Disease, Cystic Fibrosis, Drug Discovery, EU, European Medicines Agency (EMA), FDA, FDA/Regulatory, Fast Track Designation, February 2019, Future Blockbusters, Gene Editing, Generalized Myasthenia Gravis (gMG), Genomics, HIV, Human Genome, Immune Cells, Immune System, Immune-Mediated Diseases, Immunotherapy, Inflammatory Diseases, Injectables, Innovation, Integrase strand transfer inhibitors, Issue Archives, Japan, M&A, Med Ad News, Monoclonal Antibodies, Multiple myeloma, Neoantigens, Neurology, Neuromyelitis Optica Spectrum Disorder (NMOSD), New Drug Applications, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), Non-Small Cell Lung Cancer (NSCLC), Nonalcoholic Steatohepatitis (NASH), Nuclear Medicine, Oncology, Orphan Drug Designation, Paroxysmal Nocturnal Hemoglobinuria (PNH), Precision Medicine, Prescription Drug User Fee Act (PDUFA), Priority Medicines (PRIME) Designation, Priority Review Voucher, Product Pipelines, Proteins, Psoriatic Arthritis, R&D, RNA Interference (RNAi), Radioligands, Rare Disorders, Research, Rheumatoid Arthritis, Sickle Cell Disease, Small Molecules, Special Reports, T-Cells, Top 10 Pipelines, Top 10 Pipelines To Watch, Tumors, Ulcerative Colitis, Ultra Rare Diseases

The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.

February 13, 2019/by Andrew Humphreys

U.S. FDA Accepts sNDAs for Pifeltro and Delstrigo

Antiretroviral Drugs, FDA, FDA/Regulatory, HIV, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), Supplemental New Drug Application (sNDA)

Merck & Co. announced that the U.S. Food and Drug Administration accepted for review supplemental New Drug Applications (sNDAs) for Pifeltro and Delstrigo.

January 22, 2019/by Administrator

Yale Researchers Discover Immune System Protein That Can Help Suppress HIV

Apobec3A (A3A) protein, Cells, FDA, Gene Expression, HIV, Immune System, Lupus nephritis, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), R&D, T-Cells, U.S. Centers for Disease Control and Prevention, Viral Genes, Viruses

A new report released by researchers at Yale University could change the way some HIV patients are treated.

January 22, 2019/by BioSpace

Could Immunotherapy Replace Antiretrovirals in HIV Treatment?

Antibodies, Antiretroviral Drugs, Broadly Neutralizing Antibodies (bNAbs), FDA, HIV, Immunotherapies, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), R&D, Researchers, Studies

An experimental HIV immunotherapy treatment is showing significant promise in clinical testing. A study shows the two-drug combination is capable of suppressing HIV for months at a time.

September 27, 2018/by BioSpace

Merck & Co. Plans to File NDA for HIV Treatment Doravirine Based on Phase III Results

HIV, NDA/MAA, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)

HIV-positive patients may soon have a new treatment option that can be taken without food restrictions and has a much lower rate of drug interference with other medications patients may be taking.

July 26, 2017/by BioSpace